CN117180249A - 包含乳酸钙的药物组合物及其用途 - Google Patents

包含乳酸钙的药物组合物及其用途 Download PDF

Info

Publication number
CN117180249A
CN117180249A CN202311101709.6A CN202311101709A CN117180249A CN 117180249 A CN117180249 A CN 117180249A CN 202311101709 A CN202311101709 A CN 202311101709A CN 117180249 A CN117180249 A CN 117180249A
Authority
CN
China
Prior art keywords
calcium lactate
pharmaceutical composition
cancer
acid
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202311101709.6A
Other languages
English (en)
Chinese (zh)
Inventor
张宗焕
郑勤永
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MetiMedi Pharmaceuticals Co Ltd
Original Assignee
MetiMedi Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MetiMedi Pharmaceuticals Co Ltd filed Critical MetiMedi Pharmaceuticals Co Ltd
Publication of CN117180249A publication Critical patent/CN117180249A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A23L33/165—Complexes or chelates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/042—Lactic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/15—Inorganic Compounds
    • A23V2250/156—Mineral combination
    • A23V2250/1578—Calcium

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Emergency Medicine (AREA)
  • Cosmetics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202311101709.6A 2016-11-30 2017-07-07 包含乳酸钙的药物组合物及其用途 Pending CN117180249A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR1020160161931A KR20180062063A (ko) 2016-11-30 2016-11-30 서방형 항암용 약학 조성물
KR10-2016-0161931 2016-11-30
PCT/IB2017/054091 WO2018100442A1 (en) 2016-11-30 2017-07-07 Calcium lactate compositions and methods of use
CN201780073923.1A CN110087632B (zh) 2016-11-30 2017-07-07 乳酸钙组合物和使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780073923.1A Division CN110087632B (zh) 2016-11-30 2017-07-07 乳酸钙组合物和使用方法

Publications (1)

Publication Number Publication Date
CN117180249A true CN117180249A (zh) 2023-12-08

Family

ID=62242802

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202311101709.6A Pending CN117180249A (zh) 2016-11-30 2017-07-07 包含乳酸钙的药物组合物及其用途
CN201780073923.1A Active CN110087632B (zh) 2016-11-30 2017-07-07 乳酸钙组合物和使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780073923.1A Active CN110087632B (zh) 2016-11-30 2017-07-07 乳酸钙组合物和使用方法

Country Status (12)

Country Link
US (3) US11285121B2 (https=)
EP (1) EP3547999A4 (https=)
JP (1) JP2020500870A (https=)
KR (3) KR20180062063A (https=)
CN (2) CN117180249A (https=)
AR (1) AR110302A1 (https=)
AU (2) AU2017368901B2 (https=)
MX (1) MX2019006291A (https=)
MY (1) MY206468A (https=)
PH (1) PH12019501199A1 (https=)
TW (2) TWI827535B (https=)
WO (1) WO2018100442A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3087953C (en) 2018-01-12 2025-11-25 Metimedi Pharmaceuticals Co., Ltd. METHODS OF TREATMENT FOR CHRONIC INFLAMMATORY DISEASES
US12097043B2 (en) 2018-06-06 2024-09-24 Masimo Corporation Locating a locally stored medication
CN112512406A (zh) * 2018-06-06 2021-03-16 梅西莫股份有限公司 阿片类药物过量监测
KR101998246B1 (ko) * 2018-08-22 2019-07-10 주식회사 메타파인즈 금속이온에 결합된 이온화합물을 포함하는 암 치료용 약학 조성물
US11464410B2 (en) 2018-10-12 2022-10-11 Masimo Corporation Medical systems and methods
US20220265586A1 (en) * 2019-06-10 2022-08-25 Ponce De Leon Health Designated Activity Company Sustained-release compositions of alpha-ketoglutarate
EP4093507A4 (en) * 2020-01-24 2024-02-28 Barkey, Daniel, Q. WEIGHT LOSS COMPOSITIONS AND METHODS
JP7737391B2 (ja) 2020-03-20 2025-09-10 マシモ・コーポレイション 非侵襲的な体温測定のためのウェアラブルデバイス
US20230310327A1 (en) * 2020-08-03 2023-10-05 Natco Pharma Limited Pharmaceutical compositions comprising ribociclib
KR102840190B1 (ko) * 2022-04-19 2025-07-29 (의) 삼성의료재단 생리활성물질 전달체
WO2024242545A1 (ko) * 2023-05-23 2024-11-28 (주) 메티메디제약 칼슘 락테이트를 활성 성분으로 포함하는 암 백신 조성물 및 그 용도
EP4502147A1 (en) 2023-07-31 2025-02-05 M2Rlab SL Method for the polarization of cells to a new m2 phenotype and uses of said m2-polarized cells

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1961957A (zh) * 2005-11-09 2007-05-16 天津市礼人医药科技有限公司 一种抗衰老结肠吸收制剂
CN101385696A (zh) * 2008-07-29 2009-03-18 北京圣医耀科技发展有限责任公司 含依托泊苷的海藻酸钠微球血管栓塞剂及制备方法与用途
CN103316033A (zh) * 2013-07-03 2013-09-25 康晓飞 一种凝胶剂及其用途
CN104523612A (zh) * 2014-12-05 2015-04-22 海南卫康制药(潜山)有限公司 一种乳酸钙组合物咀嚼片及其制备方法
WO2016108446A1 (ko) * 2014-12-29 2016-07-07 가천대학교 산학협력단 락테이트 금속염을 포함하는 암 치료용 약학 조성물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3279997A (en) * 1963-10-22 1966-10-18 Herbert D Schneyer Enteric coated calcium lactate tablets containing an antihistamine and thiamine chloride
JPS4837815B1 (https=) * 1970-09-25 1973-11-14 Yamanouchi Pharma Co Ltd
EP0364696B1 (en) * 1988-08-22 1993-03-17 Takeda Chemical Industries, Ltd. Alpha-glucosidase inhibitor as a calcium absorption promotor
US5980951A (en) * 1996-04-10 1999-11-09 Merck & Co., Inc. Oral coated active drugs
DE10233229A1 (de) * 2002-07-22 2004-02-12 S.K. Enterprise Gmbh Pharmazeutische Zusammensetzung zur Senkung des Triglyceridspiegels
CA2509620A1 (en) * 2002-12-17 2004-07-01 Wakunaga Pharmaceutical Co., Ltd. Light-shielding agent and film-forming composition
ES2255429B1 (es) * 2004-10-25 2007-08-16 Italfarmaco, S.A. Composiciones farmaceuticas bucodispersables.
US20060280795A1 (en) * 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
UA95093C2 (uk) * 2005-12-07 2011-07-11 Нікомед Фарма Ас Спосіб одержання кальцієвмісної сполуки
TW200808380A (en) 2006-02-21 2008-02-16 Shinetsu Chemical Co Enteric-coated preparation for site-specific delivery of drug to site within the small intestine
JP2008044927A (ja) * 2006-02-21 2008-02-28 Shin Etsu Chem Co Ltd 小腸内部位特異的薬物デリバリーのための腸溶性コーティング基剤で被覆した腸溶性製剤
WO2008090569A1 (en) * 2007-01-25 2008-07-31 Panacea Biotec Ltd Modified release pharmaceutical composition and a process of making the same
CN101139281A (zh) * 2007-10-16 2008-03-12 陈杰 纳米乳酸钙及其制备方法
CN102448439A (zh) * 2009-03-26 2012-05-09 普马特里克斯公司 用于改变黏膜内衬的生物物理特性的柠檬酸钙及乳酸钙调配物
US8247000B2 (en) * 2009-04-10 2012-08-21 Cypress Pharmaceutical, Inc. Phosphate-binding magnesium salts and uses thereof
EP2599477A1 (en) 2011-11-30 2013-06-05 Lunamed AG 4-Phenylbutyric acid sustained release formulation
CN102823872B (zh) * 2012-08-22 2014-01-15 安徽泰格生物技术股份有限公司 包膜乳酸钙颗粒及其制备方法
EP2968176B1 (en) * 2013-03-15 2019-08-21 Cerolife LLC Orally administrable compositions comprising calcium
US10386359B2 (en) * 2014-05-23 2019-08-20 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for determining whether a patient will achieve a response after radiation therapy
CN107898808B (zh) * 2017-10-31 2021-04-27 华仁药业股份有限公司 小儿用静脉营养制剂

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1961957A (zh) * 2005-11-09 2007-05-16 天津市礼人医药科技有限公司 一种抗衰老结肠吸收制剂
CN101385696A (zh) * 2008-07-29 2009-03-18 北京圣医耀科技发展有限责任公司 含依托泊苷的海藻酸钠微球血管栓塞剂及制备方法与用途
CN103316033A (zh) * 2013-07-03 2013-09-25 康晓飞 一种凝胶剂及其用途
CN104523612A (zh) * 2014-12-05 2015-04-22 海南卫康制药(潜山)有限公司 一种乳酸钙组合物咀嚼片及其制备方法
WO2016108446A1 (ko) * 2014-12-29 2016-07-07 가천대학교 산학협력단 락테이트 금속염을 포함하는 암 치료용 약학 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANNA-LENA KJØNIKSEN等: "Stabilization of Pluronic Gels in the Presence of Different Polysaccharides", J. APPL. POLYM. SCI, vol. 131, no. 13, 31 December 2014 (2014-12-31), pages 1 - 8 *

Also Published As

Publication number Publication date
KR20180062063A (ko) 2018-06-08
EP3547999A1 (en) 2019-10-09
TWI841481B (zh) 2024-05-01
KR20230004968A (ko) 2023-01-06
KR20190082949A (ko) 2019-07-10
US11285121B2 (en) 2022-03-29
JP2020500870A (ja) 2020-01-16
US12059397B2 (en) 2024-08-13
CN110087632A (zh) 2019-08-02
US20190307712A1 (en) 2019-10-10
EP3547999A4 (en) 2020-07-15
AU2017368901B2 (en) 2023-10-05
AU2023229549A1 (en) 2023-09-28
CN110087632B (zh) 2023-09-19
US20220175706A1 (en) 2022-06-09
MY206468A (en) 2024-12-18
KR102512475B1 (ko) 2023-03-22
WO2018100442A1 (en) 2018-06-07
MX2019006291A (es) 2019-08-01
US20240350439A1 (en) 2024-10-24
TW201821072A (zh) 2018-06-16
TW202400132A (zh) 2024-01-01
AU2017368901A1 (en) 2019-06-13
TWI827535B (zh) 2024-01-01
AR110302A1 (es) 2019-03-13
PH12019501199A1 (en) 2020-02-24

Similar Documents

Publication Publication Date Title
CN110087632B (zh) 乳酸钙组合物和使用方法
JP6234412B2 (ja) リファキシミンの固溶体
CN104173272B (zh) 一种异硫氰酸酯类化合物的缓释制剂
ES2784843T3 (es) Complejos de Sirolimus y sus derivados, procedimiento para la preparación de los mismos y composiciones farmacéuticas que los contienen
CN111918646B (zh) 延迟释放去铁酮片剂及其使用方法
KR102616690B1 (ko) 아연-γ-PGA 조성물 및 암을 치료하기 위한 방법
EA035686B1 (ru) Препараты, содержащие 2-амино-2-[2-(4-октилфенил)этил]пропан-1,3-диол
US20180110744A1 (en) Disulfiram and metal salt staggered oral dosing regimen and staggered-release oral unit dosage forms
WO2016101807A1 (zh) 包含托吡酯的药物组合物
RU2462248C2 (ru) Стабильная фармацевтическая композиция, содержащая водорастворимую соль винфлунина
KR102725852B1 (ko) 알파-폴리글루탐산-아연을 포함하는 암 치료용 조성물
HK40103513A (zh) 包含乳酸钙的药物组合物及其用途
KR101739731B1 (ko) 유당불내성 환자에게 투여가 가능하며, 복용편의성이 향상된 게피티니브를 함유하는 약제학적 조성물
Al-Mahmood et al. Formulation and characterization of floating biphasic tablet consisting of cefdinir nanosuspension
CN111565714B (zh) 包含依维莫司的实现稳定化的药剂学制剂
TWI426929B (zh) 持續性釋放之含抗生素醫藥組合物、製備法及其應用
CA3176772A1 (en) Modified release pharmaceutical formulation comprising hydroxypropyl cellulose
EP4072552A1 (en) Chemotherapeutic drug implant
HK40031628A (en) Stabilized pharmaceutical formulation comprising everolimus
HK40031628B (en) Stabilized pharmaceutical formulation comprising everolimus
WO2018142359A1 (en) Composition comprising immediate release and extended release capecitabine
CN106361717A (zh) 一种依维莫司胃溶型微丸片及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40103513

Country of ref document: HK